Skip to main content
Top
Published in: Diabetologia 4/2010

01-04-2010 | For Debate

The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation

Authors: R. K. Simmons, K. G. M. M. Alberti, E. A. M. Gale, S. Colagiuri, J. Tuomilehto, Q. Qiao, A. Ramachandran, N. Tajima, I. Brajkovich Mirchov, A. Ben-Nakhi, G. Reaven, B. Hama Sambo, S. Mendis, G. Roglic

Published in: Diabetologia | Issue 4/2010

Login to get access

Abstract

This article presents the conclusions of a WHO Expert Consultation that evaluated the utility of the ‘metabolic syndrome’ concept in relation to four key areas: pathophysiology, epidemiology, clinical work and public health. The metabolic syndrome is a concept that focuses attention on complex multifactorial health problems. While it may be considered useful as an educational concept, it has limited practical utility as a diagnostic or management tool. Further efforts to redefine it are inappropriate in the light of current knowledge and understanding, and there is limited utility in epidemiological studies in which different definitions of the metabolic syndrome are compared. Metabolic syndrome is a pre-morbid condition rather than a clinical diagnosis, and should thus exclude individuals with established diabetes or known cardiovascular disease (CVD). Future research should focus on: (1) further elucidation of common metabolic pathways underlying the development of diabetes and CVD, including those clustering within the metabolic syndrome; (2) early-life determinants of metabolic risk; (3) developing and evaluating context-specific strategies for identifying and reducing CVD and diabetes risk, based on available resources; and (4) developing and evaluating population-based prevention strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization (2008) 2008–2013 Action plan for the global strategy for the prevention and control of noncommunicable diseases. WHO, Geneva World Health Organization (2008) 2008–2013 Action plan for the global strategy for the prevention and control of noncommunicable diseases. WHO, Geneva
2.
go back to reference United Nations (2008) The Millennium Development Goals report 2008. United Nations, New York United Nations (2008) The Millennium Development Goals report 2008. United Nations, New York
3.
go back to reference Reaven GM (1988) Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607CrossRefPubMed Reaven GM (1988) Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607CrossRefPubMed
4.
go back to reference World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. WHO, Geneva World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. WHO, Geneva
5.
go back to reference Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438CrossRefPubMed Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438CrossRefPubMed
6.
go back to reference Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443CrossRefPubMed Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443CrossRefPubMed
7.
go back to reference Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062CrossRefPubMed Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062CrossRefPubMed
8.
go back to reference Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645CrossRefPubMed Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645CrossRefPubMed
9.
go back to reference Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48:1684–1699CrossRefPubMed Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48:1684–1699CrossRefPubMed
11.
go back to reference Carr DB, Utzschneider KM, Hull RL et al (2004) Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53:2087–2094CrossRefPubMed Carr DB, Utzschneider KM, Hull RL et al (2004) Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53:2087–2094CrossRefPubMed
12.
go back to reference Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778CrossRefPubMed Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778CrossRefPubMed
13.
go back to reference Fernandez-Twinn DS, Ozanne SE (2006) Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. Physiol Behav 88:234–243CrossRefPubMed Fernandez-Twinn DS, Ozanne SE (2006) Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. Physiol Behav 88:234–243CrossRefPubMed
14.
go back to reference Sjogren M, Lyssenko V, Jonsson A et al (2008) The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia 51:2242–2251CrossRefPubMed Sjogren M, Lyssenko V, Jonsson A et al (2008) The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia 51:2242–2251CrossRefPubMed
15.
go back to reference Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRefPubMed Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRefPubMed
16.
go back to reference Vgontzas AN, Bixler EO, Chrousos GP (2005) Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 9:211–224CrossRefPubMed Vgontzas AN, Bixler EO, Chrousos GP (2005) Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 9:211–224CrossRefPubMed
17.
go back to reference Russo A, Autelitano M, Bisanti L (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44:293–297CrossRefPubMed Russo A, Autelitano M, Bisanti L (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44:293–297CrossRefPubMed
18.
go back to reference Wild SH, Byrne CD (2005) The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In: Wild SH, Byrne CD (eds) The metabolic syndrome. Wiley, Chichester, pp 1–43 Wild SH, Byrne CD (2005) The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In: Wild SH, Byrne CD (eds) The metabolic syndrome. Wiley, Chichester, pp 1–43
19.
go back to reference Weiss R, Dziura J, Burgert TS et al (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362–2374CrossRefPubMed Weiss R, Dziura J, Burgert TS et al (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362–2374CrossRefPubMed
20.
go back to reference Esmaillzadeh A, Mirmiran P, Azadbakht L, Etemadi A, Azizi F (2006) High prevalence of the metabolic syndrome in Iranian adolescents. Obesity 14:377–382CrossRefPubMed Esmaillzadeh A, Mirmiran P, Azadbakht L, Etemadi A, Azizi F (2006) High prevalence of the metabolic syndrome in Iranian adolescents. Obesity 14:377–382CrossRefPubMed
21.
go back to reference Reaven GM (2006) The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 83:1237–1247PubMed Reaven GM (2006) The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 83:1237–1247PubMed
22.
go back to reference Eddy DM, Schlessinger L, Heikes K (2008) The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes 32(Suppl 2):S5–10CrossRef Eddy DM, Schlessinger L, Heikes K (2008) The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes 32(Suppl 2):S5–10CrossRef
23.
go back to reference Lee CM, Huxley RR, Woodward M et al (2008) The metabolic syndrome identifies a heterogeneous group of metabolic component combinations in the Asia-Pacific region. Diabetes Res Clin Pract 8:377–380CrossRef Lee CM, Huxley RR, Woodward M et al (2008) The metabolic syndrome identifies a heterogeneous group of metabolic component combinations in the Asia-Pacific region. Diabetes Res Clin Pract 8:377–380CrossRef
24.
go back to reference Sattar N, McConnachie A, Shaper AG et al (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927–1935CrossRefPubMed Sattar N, McConnachie A, Shaper AG et al (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927–1935CrossRefPubMed
25.
go back to reference Kohli P, Greenland P (2006) Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 295:819–821CrossRefPubMed Kohli P, Greenland P (2006) Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 295:819–821CrossRefPubMed
26.
go back to reference Cameron AJ, Magliano DJ, Zimmet PZ et al (2008) The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 264:177–186CrossRefPubMed Cameron AJ, Magliano DJ, Zimmet PZ et al (2008) The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 264:177–186CrossRefPubMed
27.
go back to reference Mancia G, Bombelli M, Corrao G et al (2007) Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 49:40–47CrossRefPubMed Mancia G, Bombelli M, Corrao G et al (2007) Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 49:40–47CrossRefPubMed
28.
go back to reference Stevens J, McClain JE, Truesdale KP (2008) Selection of measures in epidemiologic studies of the consequences of obesity. Int J Obes 32(Suppl 3):S60–S66CrossRef Stevens J, McClain JE, Truesdale KP (2008) Selection of measures in epidemiologic studies of the consequences of obesity. Int J Obes 32(Suppl 3):S60–S66CrossRef
29.
go back to reference Canoy D (2008) Distribution of body fat and risk of coronary heart disease in men and women. Curr Opin Cardiol 23:591–598CrossRefPubMed Canoy D (2008) Distribution of body fat and risk of coronary heart disease in men and women. Curr Opin Cardiol 23:591–598CrossRefPubMed
30.
go back to reference Mendis S, Lindholm LH, Mancia G et al (2007) World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens 25:1578–1582CrossRefPubMed Mendis S, Lindholm LH, Mancia G et al (2007) World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens 25:1578–1582CrossRefPubMed
31.
go back to reference Kohro T, Furui Y, Mitsutake N et al (2008) The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome. Int Heart J 49:193–203CrossRefPubMed Kohro T, Furui Y, Mitsutake N et al (2008) The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome. Int Heart J 49:193–203CrossRefPubMed
32.
go back to reference Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297CrossRefPubMed Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297CrossRefPubMed
33.
go back to reference Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed
34.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed
35.
go back to reference Eyre H, Kahn R, Robertson RM et al (2004) Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 109:3244–3255CrossRefPubMed Eyre H, Kahn R, Robertson RM et al (2004) Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 109:3244–3255CrossRefPubMed
Metadata
Title
The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation
Authors
R. K. Simmons
K. G. M. M. Alberti
E. A. M. Gale
S. Colagiuri
J. Tuomilehto
Q. Qiao
A. Ramachandran
N. Tajima
I. Brajkovich Mirchov
A. Ben-Nakhi
G. Reaven
B. Hama Sambo
S. Mendis
G. Roglic
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1620-4

Other articles of this Issue 4/2010

Diabetologia 4/2010 Go to the issue